Insider Transactions in Q2 2025 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,198
-15.53%
|
$68,178
$11.33 P/Share
|
|
Apr 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,438
-5.76%
|
$26,818
$11.5 P/Share
|
|
Apr 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+6.79%
|
-
|
|
Apr 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,894
-7.2%
|
$31,834
$11.5 P/Share
|
|
Apr 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+6.34%
|
-
|
|
Apr 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,377
-5.2%
|
$37,147
$11.5 P/Share
|
|
Apr 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,956
+4.59%
|
-
|